Abstract |
Telmisartan, an angiotensin II type 1-receptor blocker (ARBs), has been reported to exert beneficial effects on the central nervous system (CNS). However, the effect of telmisartan on cognitive impairment associated with type 1 diabetes is not well known. Here, we examined the possibility that telmisartan could improve memory function in a type 1 diabetic mouse model, streptozotocin (STZ)-induced diabetic mice. STZ-induced diabetic mice subjected to the Morris Water Maze (MWM) task exhibited a significant decline of spatial learning and memory. Oral administration of telmisartan at two nonhypotensive doses (0.7 or 0.35 mg/kg) significantly improved memory deficits in STZ-induced diabetic mice. Telmisartan treatment markedly reduced Aβ₄₂, APP, BACE1, RAGE, and NF-κB p65 of the hippocampus and cortex, but did not beneficially affect hyperglycemia and hypoinsulinemia in the STZ-induced diabetic mice compared with untreated diabetic mice. Taken together, our findings suggest that telmisartan ameliorates memory deficits in type 1 diabetic mice, at least partly because of attenuation of amyloidosis in the brain.
|
Authors | Guan Tao Du, Meng Hu, Zhen Lin Mei, Chao Wang, Guang Jun Liu, Mei Hu, Yan Long, Ming Xing Miao, Jia Chang Li, Hao Hong |
Journal | Journal of pharmacological sciences
(J Pharmacol Sci)
Vol. 124
Issue 4
Pg. 418-26
( 2014)
ISSN: 1347-8648 [Electronic] Japan |
PMID | 24671053
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Amyloid beta-Peptides
- Amyloid beta-Protein Precursor
- Angiotensin II Type 1 Receptor Blockers
- Benzimidazoles
- Benzoates
- Peptide Fragments
- Receptor for Advanced Glycation End Products
- Transcription Factor RelA
- amyloid beta-protein (1-42)
- Streptozocin
- Amyloid Precursor Protein Secretases
- Aspartic Acid Endopeptidases
- Bace1 protein, mouse
- Telmisartan
|
Topics |
- Administration, Oral
- Amyloid Precursor Protein Secretases
(metabolism)
- Amyloid beta-Peptides
(metabolism)
- Amyloid beta-Protein Precursor
(metabolism)
- Angiotensin II Type 1 Receptor Blockers
(administration & dosage, pharmacology, therapeutic use)
- Animals
- Aspartic Acid Endopeptidases
(metabolism)
- Benzimidazoles
(administration & dosage, pharmacology, therapeutic use)
- Benzoates
(administration & dosage, pharmacology, therapeutic use)
- Cerebral Amyloid Angiopathy
(drug therapy, etiology)
- Cerebral Cortex
(metabolism)
- Diabetes Mellitus, Experimental
(complications)
- Diabetes Mellitus, Type 1
(complications)
- Disease Models, Animal
- Hippocampus
(metabolism)
- Male
- Memory Disorders
(drug therapy, etiology)
- Mice
- Mice, Inbred ICR
- Peptide Fragments
(metabolism)
- Receptor for Advanced Glycation End Products
(metabolism)
- Streptozocin
- Telmisartan
- Transcription Factor RelA
(metabolism)
- Treatment Outcome
|